Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine Inc. (NASDAQ: CMND) has announced promising results from a pre-clinical trial involving 2-Fluorodeschloroketamine (2-FDCK), an analogue of Ketamine, aimed at treating Major Depressive Disorder (MDD). Conducted in collaboration with Bar-Ilan University, the trial evaluated the effects of 2-FDCK on rodent models of depression. Results indicated superior efficacy of 2-FDCK over Ketamine, especially in chronic treatment settings. Clearmind's CEO highlighted the significance of these findings for patients with treatment-resistant depression, emphasizing the company's commitment to developing innovative psychedelic-derived therapeutics.

Clearmind Medicine (NASDAQ: CMND) announced its participation at Isranalytica 2023, a leading analytical chemistry conference. Professor Joseph Tam presented promising pre-clinical trial results for MEAI, its drug candidate aimed at treating obesity and metabolic syndrome. Tam's presentation titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications" showcased the drug's efficacy. CEO Dr. Adi Zuloff-Shani emphasized the importance of raising awareness within the scientific community to support future clinical programs. Clearmind focuses on developing psychedelic-derived therapeutics for untreated health issues.

Clearmind Medicine Inc. (Nasdaq, CSE: CMND) recently announced the successful completion of two innovative drug-discovery projects at the Hebrew University. These projects focus on developing novel psychedelic compounds aimed at enhancing therapeutic effects for under-treated health issues. Led by esteemed professors, the initiatives involved synthesizing synthetic molecules and evaluating psychedelic analogues for efficacy and safety. The promising results from these projects will allow Clearmind and Yissum to advance multiple new patent applications, expanding the company’s intellectual property portfolio. The firm remains committed to its mission of providing innovative solutions for mental health challenges.

Clearmind Medicine Inc. (CMND) announced promising pre-clinical results for its drug candidate MEAI, showing potential in treating substance addiction without affecting natural reward processes. Conducted at Bar Ilan University, the in-vivo studies revealed that MEAI, at a dose of 5mg/kg, significantly decreased cocaine craving, marking it as a potential first-of-its-kind treatment for cocaine addiction. The researchers confirmed that MEAI allows for the maintenance of natural rewards, distinguishing it from traditional addiction treatments. CEO Dr. Adi Zuloff-Shani emphasized the importance of these results in addressing cocaine addiction, which currently lacks dedicated therapies.

Clearmind Medicine Inc. (Nasdaq: CMND) has successfully manufactured batches of its MEAI-based molecule, CMND-100, for its first in-human clinical trial targeting Alcohol Use Disorder (AUD). This milestone indicates readiness to proceed with clinical testing. The drug was produced under Good Manufacturing Practices to meet FDA standards, aligning with the company's goal to develop psychedelic-derived therapeutics. Clearmind holds seven patent families and aims to expand its intellectual property portfolio as it advances its clinical program.

Clearmind Medicine Inc. (CMND) announced promising pre-clinical trial results for its drug candidate MEAI, aimed at treating obesity and metabolic syndrome. Conducted at the Hebrew University of Jerusalem, the trials demonstrated a 20% weight loss in rodents, improved insulin sensitivity, and reduced liver fat. MEAI treatment also decreased sucrose preference, indicating potential applications in addiction treatment. The global obesity drug market was valued at $1.9 billion in 2021, with further growth projected. Clearmind's progress underscores the drug's potential to address significant health issues.

Clearmind Medicine Inc. (NASDAQ:CMND) announces a new interview featuring CEO Dr. Adi Zuloff-Shani, discussing the company's innovative approach using non-hallucinogenic psychedelic compounds to address addiction and mental health issues. Clearmind's lead candidate, CMND-100, derived from MEAI, aims to treat alcohol use disorder and is set for clinical trials in early 2023. The company holds seven patent families and has received a patent for using MEAI as an alcohol substitute. The interview addresses the significant market need for effective treatments and outlines plans for an IND application to the FDA for clinical trials.

Clearmind Medicine Inc. (CMND) held its shareholder meeting on December 28, 2022, where all proposed matters were approved. This includes the company's rolling stock option plan and an increase in options and restricted share units available for issuance. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health issues, holding seven patent families and planning further acquisitions of intellectual property. The company aims to commercialize its products as regulated medicines, foods, or supplements.

Clearmind Medicine Inc. (CMND) announced its first first-in-human clinical trial in Israel for the MEAI-based CMND-100 compound targeting alcohol use disorder (AUD). The agreement with the IMCA center in Ramat Gan will be led by Prof. Mark Weiser. CMND plans to establish a similar agreement in the U.S.. AUD affects nearly 28 million adults in the U.S., with significant public health implications. The global AUD treatment market is projected to grow from $564 million in 2021, at an annual rate of 8.8% by 2032.